TCGA-BA-4077-01B-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.25890411
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.490
- E2F_TARGETS+0.430
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.410
- COMPLEMENT+0.400
- INFLAMMATORY_RESPONSE+0.380
- ESTROGEN_RESPONSE_LATE+0.320
- MTORC1_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.290
- OXIDATIVE_PHOSPHORYLATION-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.180
- WNT_BETA_CATENIN_SIGNALING-0.110
- ANGIOGENESIS-0.050
- MYC_TARGETS_V1-0.040
- HEDGEHOG_SIGNALING-0.030
- PROTEIN_SECRETION-0.020
- UV_RESPONSE_DN-0.010
- TGF_BETA_SIGNALING+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0BD-01A-11R-A034-07 | — | A | 0.840 |
| 2 | DRR168605 | — | — | 0.837 |
| 3 | d00dcdf0-3e98-41c5-9978-7a0ffceefa6c | — | — | 0.813 |
| 4 | s0094235 | — | — | 0.811 |
| 5 | 957a7228-3558-48fd-81d9-13f951e0b597 | — | — | 0.808 |
| 6 | GSM5359441 | — | — | 0.808 |
| 7 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.805 |
| 8 | b428d434-2904-4f67-a66f-b7928e2951e3 | — | — | 0.803 |
| 9 | GSM6454748 | — | C | 0.803 |
| 10 | MDT-AP-2990 | Med | Medulloblastoma | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |